মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →Fesotrex ER
Rx4 mg • ট্যাবলেট (এক্সটেন্ডেড রিলিজ)
ইঙ্গিত ও ব্যবহার
Adult Overactive Bladder: Fesotrex ER is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.Pediatric Neurogenic Detrusor Overactivity: Fesotrex ER is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Overactive Bladder in adults: The recommended starting dosage is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of 8 mg once daily.Neurogenic Detrusor Overactivity in pediatric patients 6 years and older: Pediatric Patients Weighing Greater than 25 kg and up to 35 kg: The recommended dosage is 4 mg orally once daily. If needed, dosage may be increased to 8 mg orally once daily. Pediatric Patients Weighing Greater than 35 kg: The recommended starting dosage is 4 mg orally once daily. After one week, increase to 8 mg orally once daily. Administration: Swallow whole with liquid. Do not chew, divide, or crush. Take with or without food.Pediatric Use: The safety and effectiveness of Toviaz have been established for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 6 years and older and weighing greater than 25 kg.Geriatric Use: No dose adjustment is recommended for the elderly. The pharmacokinetics of fesoterodine are not significantly influenced by age.
পার্শ্বপ্রতিক্রিয়া
Most frequently reported adverse events with Fesotrex ER in adult patients with OAB (≥4%) were: dry mouth (placebo, 7%; Fesotrex ER 4 mg, 19%; Fesotrex ER 8 mg, 35%) and constipation (placebo, 2%; Fesotrex ER 4 mg, 4%; Fesotrex ER 8 mg, 6%).Most frequently reported adverse reactions with Fesotrex ER in pediatric patients (≥2%) with NDO were: diarrhea, urinary tract infection (UTI), dry mouth, constipation, abdominal pain, nausea, weight increased, and headache.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Angioedema: Promptly discontinue Fesotrex ER and provide appropriate therapy.Urinary Retention: Fesotrex ER is not recommended in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.Decreased Gastrointestinal Motility: Fesotrex ER is not recommended for use in patients with decreased gastrointestinal motility, such as those with severe constipation.Worsening of Narrow-Angle Glaucoma: Use Fesotrex ER with caution in patients being treated for narrow-angle glaucoma.Central Nervous System Effects: Somnolence has been reported with Fesotrex ER. Advise patients not to drive or operate heavy machinery until they know how Fesotrex ER affects them.Worsening of Myasthenia Gravis Symptoms: Use Fesotrex ER with caution in patients with myasthenia gravis.
নিষেধাজ্ঞা
Fesoterodine is contraindicated in patients with any of the following: known or suspected hypersensitivity to Fesoterodine or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules. Reactions have included angioedema. urinary retention gastric retention uncontrolled narrow-angle glaucoma.